| 刘满卓,王 慧,赵素霞,梅 丽,张祥建.尤瑞克林联合血管内介入对急性脑梗死患者神经功能、炎性因子和血液流变学的影响[J].,2020,(13):2556-2559 |
| 尤瑞克林联合血管内介入对急性脑梗死患者神经功能、炎性因子和血液流变学的影响 |
| Effects of Urinary Kallidinogenase Combined with Intravascular Intervention on Neurological Function, Inflammatory Factors and Hemorheology in Patients with Acute Cerebral Infarction |
| 投稿时间：2020-02-05 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.13.033 |
| 中文关键词: 尤瑞克林 血管内介入 急性脑梗死 神经功能 炎性因子 血液流变学 |
| 英文关键词: Urinary kallidinogenase Intravascular intervention Acute cerebral infarction Neurological function Inflammatory factors Hemorheology |
| 基金项目:河北省医学科学研究重点计划项目（20181011） |
|
| 摘要点击次数: 704 |
| 全文下载次数: 406 |
| 中文摘要: |
| 摘要 目的：探讨血管内介入联合尤瑞克林对急性脑梗死（ACI）患者炎性因子、血液流变学以及神经功能的影响。方法：选取我院于2017年4月~2019年12月间收治的80例ACI患者，采用随机数字表法分为对照组（n=40）和研究组（n=40），对照组给予血管内介入溶栓治疗，研究组在对照组基础上联合尤瑞克林治疗，比较两组患者疗效、神经功能、炎性因子、血液流变学和不良反应。结果：研究组治疗14 d后的临床总有效率为90.00%（36/40），高于对照组的72.50%（29/40）（P<0.05）。两组治疗14 d后血清白介素-6（IL-6）、白介素-1β（IL-1β）、单核细胞趋化蛋白-1(MCP-1)水平、美国国立卫生研究院卒中量表（NIHSS）评分以及血浆黏度、全血黏度高切、全血黏度低切、红细胞聚集指数均较治疗前下降，且研究组低于对照组（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：尤瑞克林联合血管内介入治疗ACI患者，疗效显著，可有效改善机体神经功能、炎性因子和血液流变学，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of urinary kallidinogenase combined with intravascular intervention on neurologic function, inflammatory factors and hemorheology in patients with acute cerebral infarction (ACI). Methods: 80 patients with ACI who were admitted to our hospital from April 2017 to December 2019 were selceted, they were randomly divided into control group (n=40) and study group (n=40). The control group was given intravascular thrombolytic therapy, and the study group was treated with urinary kallidinogenase on the basis of the control group. The efficacy, neurological function, inflammatory factors, hemorheology and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the study group at 14d after treatment was 90.00% (36/40), which was higher than 72.50% (29/40) of the control group (P<0.05). The levels of serum interleukin-6 (IL-6), interleukin-1β (IL-1β), monocyte chemotactic protein 1 (MCP-1), National institutes of health stroke scale (NIHSS) score, plasma viscosity, high whole blood viscosity, low whole blood viscosity and red blood cell aggregation index of the two groups at 14 d after treatment decreased than those before treatment, and the study group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Urinary kallidinogenase combined with intravascular intervention in the treatment of ACI is effective, which can effectively improve the nervous function, inflammatory factors and hemorheology, and which has a good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
